hunter williams retatrutide The Tesamorelin Masterclass | The Complete User's Guide (2026) - The Podcast The Hunter Williams Podcast podcast

However, ONeil added an important caveat, reminding patients not to make too much of day-to-day gains or losses

In the Phase 2 trial, weight loss continued at 48 weeks across all dose groups, suggesting retatrutide may not plateau as single-receptor medications often do

This powerful combination can lead to long-term weight management and better overall health

Employer coalitions could pool risk, subscription models may spread costs more predictably, and outcomes-based contracts could tie payments to real-world health improvements

Its long half-life means once-weekly dosing maintains stable blood levels, which is ideal both for efficacy and patient adherence